Navigation Links
Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
Date:12/8/2011

HORSHAM, Pa., Dec. 8, 2011 /PRNewswire-FirstCall/ -- Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ), announced today that it has executed an agreement with Pharmacyclics, Inc. (Nasdaq: PCYC) to jointly develop and market the anti-cancer compound, PCI-32765.  A number of Phase 1 and 2 studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.  Interim data were reported at the 2011 American Society of Clinical Oncology Annual Meeting and oral presentations on two separate Phase 2 studies will be presented at the upcoming American Society of Hematology Meeting in December, along with several other poster presentations.

"The agreement with Pharmacyclics is an opportunity to bring a new form of oral therapy to patients with B-cell malignancies," said William N. Hait, M.D., Ph.D., Global Therapeutic Head, Oncology, for Janssen.  "PCI-32765 is an innovative compound, with broad applicability and the potential to help a large number of patients with B-cell malignancies."

According to the terms of the agreement, the companies have entered into a worldwide 50/50 profit-loss agreement, sharing development and commercialization activities.  Janssen has made an upfront payment of $150 million which will be recorded in the fourth quarter, and will make additional payments based upon the achievement of certain development and regulatory milestones.  This transaction is expected to have a dilutive impact to Johnson & Johnson's 2011 earnings per share of approximately $0.04 - $0.05.

About PCI-32765

PCI-32765 is an orally active, small molecule inhibitor of Bruton's tyrosine k
'/>"/>

SOURCE Janssen Pharmaceutical Companies of Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research
2. FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application
3. Skyline Diagnostics Establishes Research Collaboration With Janssen
4. Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research
5. Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research
6. Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research
7. Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement
8. C3i Inc to Provide Full-Service Technology Support and Oracle Clinical, Oracle Remote Data Capture Business Process Outsourcing to XBiotech, Inc
9. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
10. For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
11. For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
(Date:7/10/2014)... July 10, 2014 On July ... Medvedev , presented Russia,s first ... . The Company is developing a unique project called ... BIOCAD develops a number of innovative drugs based on ... The ceremony took place at the International Exhibition "Innoprom ...
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... MRIGlobal, an internationally recognized research and development organization ... has appointed Richard A. Winegar, Ph.D., to Principal Advisor ... Dr. Winegar is a recognized expert in ... genetic toxicology.  As Principal Advisor for Science, he will ...
... July 11, 2011 Avisena, one of the nation,s ... for physician practices, today announced the extension of a ... facility will be used to accelerate the Company,s strategic ... and marketing. "Square 1 believes in supporting ...
... Pharma, Inc. is pleased to announce that it has ... its lead drug for the treatment of stroke and ... A Phase 1, Open-Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Single ... of Oral and Intravenous Administration of Methamphetamine Hydrochloride in ...
Cached Biology Technology:MRIGlobal Appoints Richard A. Winegar, Ph.D., as Principal Advisor for Science 2Avisena Closes $2.5 Million of Debt Capital By Square 1 Bank 2Sinapis Pharma Completes Phase I Trial 2
(Date:7/14/2014)... oxygen control insect body size? What influence does genetics have ... of Current Opinion in Insect Science launched ... Current Opinion in Insect Science is the latest ... review journal that aims to provide specialists with a unique ... published in the field of insect science. First articles published ...
(Date:7/14/2014)... with roots in the local environment manage much better ... from foreign environments. , A world without bees ... Denmark alone an additional 600 million to 1 billion ... done by bees making honey and pollinating a wide ... , Unfortunately, bees all over the world are under ...
(Date:7/14/2014)... genes that improved the harvesting of sunlight, a new ... genomes reveals. The findings could help current efforts to ... a ,genetic snapshot, of maize as it existed 10 ... of its genome a ,whole genome duplication, event. ... ,copied, genes to cope with the pressures of domestication, ...
Breaking Biology News(10 mins):Best for bees to be stay-at-homes 2A-maize-ing double life of a genome 2
... gases and increase production at the same time has been ... Industries' (DPI) Wollongbar Agricultural Institute. , Trials of agrichar - ... and the environment - have doubled and, in one case, ... tonnes per hectare. , Agrichar is a black ...
... tiger now occupies a mere 7 percent of its historic ... has declined by 41 percent over the past decade, according ... BioScience. Growing trade in folk medicines made from tiger parts ... believed to be the chief reason for the losses. The ...
... long been clear that smoking causes cancer, but new research ... who smokes. , Canadian researchers have demonstrated in ... of sperm cells, alterations that could potentially be inherited by ... June 1 issue of Cancer Research, a journal of the ...
Cached Biology News:Soils offer new hope as carbon sink 2Soils offer new hope as carbon sink 3Threats to wild tigers growing 2Cigarette smoke alters DNA in sperm, genetic damage could pass to offspring 2
Mouse monoclonal antibody raised against a partial recombinant EBI3. NCBI Entrez Gene ID = EBI3...
... AS-2055 and AS-2057 are fully automatic sample ... possible level of precision. Sampling flexibility is ... (microplate) for,laboratory automation and combinatorial chemistry. Also ... or the standard rack for 50 2,ml ...
...
... Covance's BCIP/NBT Chromogen system ... Tetrazolium] chromogen in a single ... reacts in the presence of ... purple staining with minimal background ...
Biology Products: